BR0317177A - Preparações de liberação controlada compreendendo tramadol e topiramato - Google Patents

Preparações de liberação controlada compreendendo tramadol e topiramato

Info

Publication number
BR0317177A
BR0317177A BR0317177-9A BR0317177A BR0317177A BR 0317177 A BR0317177 A BR 0317177A BR 0317177 A BR0317177 A BR 0317177A BR 0317177 A BR0317177 A BR 0317177A
Authority
BR
Brazil
Prior art keywords
tramadol
controlled release
topiramate
release preparations
effective amount
Prior art date
Application number
BR0317177-9A
Other languages
English (en)
Inventor
Dieter Bachmann
Reza Eivaskhani
Christian Braun
Rene Spycher
Brian Strong
Original Assignee
Cilag Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag Ag filed Critical Cilag Ag
Publication of BR0317177A publication Critical patent/BR0317177A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

"PREPARAçõES DE LIBERAçãO CONTROLADA COMPREENDENDO TRAMADOL E TOPIRAMATO". A presente invenção refere-se a uma preparação farmacêutica oral, adequada para dosagem a cada 24 horas, compreendendo um substrato, cujo substrato compreende uma quantidade farmaceuticamente eficaz de tramadol ou um sal deste e uma quantidade farmaceuticamente eficaz de topiramato e onde o referido substrato pode ser revestido com um revestimento de liberação controlada; a referida preparação tendo uma taxa de dissolução específica in vitro.
BR0317177-9A 2002-12-13 2003-12-12 Preparações de liberação controlada compreendendo tramadol e topiramato BR0317177A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02080325 2002-12-13
EP03075123 2003-01-10
PCT/EP2003/014474 WO2004054571A1 (en) 2002-12-13 2003-12-12 Controlled release preparations comprising tramadol and topiramate

Publications (1)

Publication Number Publication Date
BR0317177A true BR0317177A (pt) 2005-10-25

Family

ID=32598791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317177-9A BR0317177A (pt) 2002-12-13 2003-12-12 Preparações de liberação controlada compreendendo tramadol e topiramato

Country Status (15)

Country Link
US (1) US20060147527A1 (pt)
EP (1) EP1572192A1 (pt)
JP (1) JP2006514986A (pt)
KR (1) KR20050075408A (pt)
AR (1) AR042472A1 (pt)
AU (1) AU2003296672A1 (pt)
BR (1) BR0317177A (pt)
CA (1) CA2506807A1 (pt)
CL (1) CL2003002621A1 (pt)
MX (1) MXPA05006210A (pt)
MY (1) MY148475A (pt)
PL (1) PL377351A1 (pt)
RU (1) RU2005122008A (pt)
TW (1) TW200427448A (pt)
WO (1) WO2004054571A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
MXPA05000232A (es) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20070224281A1 (en) 2004-07-22 2007-09-27 Amorepacific Corporation Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
CN101272815B (zh) 2005-08-26 2012-09-26 明尼苏达大学董事会 器官和组织的脱细胞化和再细胞化
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
JP5349290B2 (ja) * 2006-04-03 2013-11-20 オディディ，イサ 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
TWI504419B (zh) * 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2555066T3 (es) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
US20080131501A1 (en) * 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
ES2562799T3 (es) * 2008-08-19 2016-03-08 Adcock Ingram Intellectual Property (Pty) Limited Administración a velocidad modulada de fármacos desde un comprimido de tres capas que comprende tramadol, diclofenaco, paracetamol
WO2010080603A2 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
WO2011123497A1 (en) 2010-03-31 2011-10-06 Supernus Pharmaceuticals Inc. Stabilized formulations of cns compounds
PL2611472T3 (pl) 2010-09-01 2017-02-28 Regents Of The University Of Minnesota Metody recelularyzacji tkanki lub narządu w celu poprawy wszczepialności
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
DK3730132T3 (da) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko
US9290738B2 (en) 2012-06-13 2016-03-22 Miromatrix Medical Inc. Methods of decellularizing bone
US8652527B1 (en) * 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2970891B1 (en) 2013-03-15 2020-10-21 Miromatrix Medical Inc. Use of perfusion decellularized liver for islet cell recellularization
EP3509651B1 (en) 2016-09-06 2022-12-28 Miromatrix Medical Inc. Use of resected liver serum for whole liver engineering
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
JPH0474515A (ja) * 1990-07-13 1992-03-09 Toray Ind Inc 酸素吸収体
MX9205106A (es) * 1991-09-06 1993-05-01 Johnson & Johnson Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso
AU651247B2 (en) * 1991-09-06 1994-07-14 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
WO2003035760A2 (en) * 2001-10-25 2003-05-01 Asahi Kasei Chemicals Corporation Polyphenylene sulfide resin composition
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof

Also Published As

Publication number Publication date
WO2004054571A1 (en) 2004-07-01
US20060147527A1 (en) 2006-07-06
AU2003296672A1 (en) 2004-07-09
PL377351A1 (pl) 2006-01-23
CA2506807A1 (en) 2004-07-01
JP2006514986A (ja) 2006-05-18
CL2003002621A1 (es) 2005-03-11
KR20050075408A (ko) 2005-07-20
RU2005122008A (ru) 2006-02-10
MY148475A (en) 2013-04-30
TW200427448A (en) 2004-12-16
AR042472A1 (es) 2005-06-22
EP1572192A1 (en) 2005-09-14
MXPA05006210A (es) 2005-08-19

Similar Documents

Publication Publication Date Title
BR0317177A (pt) Preparações de liberação controlada compreendendo tramadol e topiramato
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ATE202280T1 (de) Filmbildende pharmazeutische zusammensetzungen zur transdermalen verabreichung
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9910928A (pt) Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina
DE69822209D1 (de) ESTRON-SULFatase HEMMENDE ESTRON-SULFAMATVERBINDUNGEN, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR9612309A (pt) Composto uso de um composto composição farmacêutica formulação farmacêutica de aerossol combinação e processos para o tratamento de um indivíduo humano ou animal com uma condição anti-inflamatória e/ou alérgica e para a preparação de um composto
BR9906920A (pt) "tts contendo um antioxidante"
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BR0211198A (pt) Composições farmacêuticas e seu uso
BR9913135A (pt) Formulação oral
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S),

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.